Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Myriad Genetics, Inc. (MYGN : NSDQ)
 
 • Company Description   
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.

Number of Employees: 2,400

 
 • Price / Volume Information   
Yesterday's Closing Price: $21.97 Daily Weekly Monthly
20 Day Moving Average: 569,930 shares
Shares Outstanding: 80.34 (millions)
Market Capitalization: $1,765.14 (millions)
Beta: 1.57
52 Week High: $36.95
52 Week Low: $18.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 0.37% 13.03%
12 Week -13.74% -5.18%
Year To Date -20.40% -4.64%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
320 WAKARA WAY
-
SALT LAKE CITY,UT 84108
USA
ph: 801-584-3600
fax: 801-584-3640
sgleason@myriad.com http://www.myriad.com
 
 • General Corporate Information   
Officers
Paul J. Diaz - Chief Executive Officer; President and Director
S. Louise Phanstiel - Chair of the Board
R. Bryan Riggsbee - Chief Financial Officer
Heiner Dreismann - Director
Rashmi Kumar - Director

Peer Information
Myriad Genetics, Inc. (CORR.)
Myriad Genetics, Inc. (RSPI)
Myriad Genetics, Inc. (CGXP)
Myriad Genetics, Inc. (BGEN)
Myriad Genetics, Inc. (GTBP)
Myriad Genetics, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 62855J104
SIC: 2835
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/02/22
Share - Related Items
Shares Outstanding: 80.34
Most Recent Split Date: 3.00 (2.00:1)
Beta: 1.57
Market Capitalization: $1,765.14 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.32 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/02/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.86
Price/Cash Flow: 47.01
Price / Sales: 2.59
EPS Growth
vs. Year Ago Period: 12.50%
vs. Previous Quarter: -27.27%
Sales Growth
vs. Year Ago Period: -4.74%
vs. Previous Quarter: 2.55%
ROE
03/31/22 - -2.75
12/31/21 - -2.93
09/30/21 - -3.70
ROA
03/31/22 - -1.97
12/31/21 - -2.03
09/30/21 - -2.46
Current Ratio
03/31/22 - 2.57
12/31/21 - 2.37
09/30/21 - 2.46
Quick Ratio
03/31/22 - 2.48
12/31/21 - 2.30
09/30/21 - 2.36
Operating Margin
03/31/22 - -3.81
12/31/21 - -3.94
09/30/21 - -4.91
Net Margin
03/31/22 - -1.20
12/31/21 - -3.94
09/30/21 - -9.32
Pre-Tax Margin
03/31/22 - -4.97
12/31/21 - -8.27
09/30/21 - 23.55
Book Value
03/31/22 - 11.83
12/31/21 - 12.12
09/30/21 - 12.13
Inventory Turnover
03/31/22 - 11.63
12/31/21 - 10.37
09/30/21 - 2.61
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©